Press Releases April 22, 2026 08:00 AM

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29

MiMedx to Report Q1 2026 Financial Results and Host Conference Call on April 29

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
MDXG

MiMedx Group, Inc., a leader in wound care and regenerative medicine, announced it will release its first quarter 2026 financial results after market close on April 29, 2026, followed by a webcast and conference call with senior management to discuss operating and financial performance.

MIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29
MDXG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • MiMedx will report Q1 2026 results after market close on April 29, 2026.
  • A conference call and webcast will follow at 4:30 p.m. ET to discuss the results.
  • The company focuses on healing solutions in wound care, burn, and surgical healthcare sectors.
  • This event allows investors and analysts to gauge company performance and outlook in the regenerative medicine sector.

MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, April 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

The conference call can be accessed using the following information:

Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13759618

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.

Contact:
Matt Notarianni
Investor Relations
470-304-7291
[email protected]


Risks

  • Market reaction depends on financial results which are currently unknown, introducing uncertainty.
  • The wound care and regenerative medicine sectors can be sensitive to regulatory changes and reimbursement policies.
  • Operational risks include competition and innovation pace which can impact MiMedx's market position and growth.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026